Dr Adeola Ayoola

Medical Oncologist
Become a Patient

With a passion for clinical research and precision oncology using theranostics and genomic markers, Dr Adeola Ayoola is dedicated to delivering personalised treatment plans for those in his care.


Dr Adeola Ayoola is an experienced medical oncologist and molecular imaging specialist at Icon Cancer Centre Townsville. He completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at Obafemi Awolowo College of Health Sciences and commenced post graduate medical training in the management of acute medical conditions at leading New Zealand and Australian hospitals. Dr Ayoola completed specialist medical oncology training at Calvary Mater Hospital followed by an oncology clinical trials research fellowship at Flinders Centre for Innovation in Cancer, investigating phase I to IV clinical trials. After becoming a Fellow of Royal Australasian College of Physicians (FRACP), he subsequently completed further sub-speciality training in nuclear medicine applications in oncology (molecular imaging and theranostics) at the Royal Brisbane and Women’s Hospital and John Hunter Hospital.

Dr Ayoola maintains a strong interest in education, research and clinical trials, actively engaging in medical student and registrar education through his clinical lecturer position at Macquarie University. He has co-authored several journal articles in leading national and international medical publications and developed clinical oncology protocols for the treatment of neuroendocrine tumours and chemotherapy-induced diarrhoea. Dr Ayoola is a regular invited speaker at national and international medical conferences to present on molecular imaging and theranostics. He is an alumnus of the London Imperial College Business School where he recently completed his Master of Business Administration, graduating with a Merit.

Dr Ayoola collaborates with other genomic experts to deliver cancer genome analysis; this personalised approach explores other potential treatment modalities based on specific mutations present in those cancer cells. His clinical experience covers a broad range of solid tumour malignancies with a special interest in melanoma, prostate cancer, colon cancer and breast cancer.

Affiliations & Memberships

  • Australasian Association of Nuclear Medicine Specialists (AANMS)
  • Medical Oncology Group of Australia (MOGA)
  • Royal Australian College of Physicians (RACP)
  • Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Special Interests

Dr Adeola Ayoola accepts referrals for all cancer types, with a special clinical interest in:
  • Breast cancer
  • Clinical research
  • Colorectal cancer
  • Melanoma
  • Prostate cancer

Icon Locations

Townsville View centre

Visiting Locations

  • St Andrew’s Ipswich Private Hospital
  • Macquarie University Hospital


  • Influenza Vaccine effectiveness during cancer treatment. This study answers an important clinical question, how effective is influenza vaccine on patients who are on treatment for various types of cancer. As we know, Influenza virus infection has significant morbidity and mortality in those with medical conditions and who are immunosuppressed. We assessed the efficacy of seasonal influenza vaccine in patients with non-haematological malignancy on active treatment (chemotherapy and targeted therapy). Efficacy of influenza vaccine (Fluvax) in cancer patients on treatment: a prospective single arm, open-label study. Supportive Care in Cancer, 2020.  

  • Stage III Lung cancer, chemoradiation, long term toxicity. The preferred management of patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemo-radiotherapy (CRT). This treatment has well documented short toxic side effects, however, less is known about late toxicities. We reviewed the long-term and any late toxicities in Stage III NSCLC treated with chemoradiotherapy. Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced (stage iii) non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up. Journal of Thoracic Disease, 2019. 11(10): 4241-4248.

  • A commentary on Liver directed therapy, Selective Internal Radiation Therapy (SIRT). In patients with metastatic colorectal cancer, liver metastatic-related complications remain one of the major causes of death. Selective internal radiation therapy (SIRT) is a liver-directed treatment that aims to achieve control of metastatic liver lesions that are not amenable to surgery. Previous studies have shown some activity as a salvage therapy in patients with chemo-refractory disease. SIRFLOX: Progression-free survival in the liver as a surrogate end point for survival. Journal of Clinical Oncology, 2016. 34(34): 4193.

  • Decision making in Testicular Cancer, Stage I. Involving patients in the treatment decision making process is an important aspect of patient-centred care. However, patient’s preferences for involvement are not always met. This was a retrospective survey study, which assessed a range of factors concerning the treatment decision making process of testicular cancer patients. Decision-making preferences and satisfaction of stage one testicular cancer patients. Asia-Pacific Journal of Clinical Oncology, 2016. 12(5): 23.

  • Decision aid, testicular cancer, Stage I. Chemotherapy or surveillance are recommended treatments for stage 1 testicular cancer patients, post-surgery. Both are effective but have distinct pros and cons that may be valued differently, thus making treatment decisions preference sensitive. Decision aids are effective and may help support these treatment decisions. Assessing the information needs of stage one testicular cancer patients and their Carers. Asia-Pacific Journal of Clinical Oncology, 2016. 12(5): 13.